Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R. Oliva EN, et al. Among authors: ghio r. Ann Hematol. 2013 Jan;92(1):25-32. doi: 10.1007/s00277-012-1569-0. Epub 2012 Sep 16. Ann Hematol. 2013. PMID: 22983750 Clinical Trial.
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R. Oliva EN, et al. Among authors: ghio r. Eur J Haematol. 2010 Sep;85(3):231-5. doi: 10.1111/j.1600-0609.2010.01473.x. Epub 2010 May 17. Eur J Haematol. 2010. PMID: 20491881 Clinical Trial.
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R. Balleari E, et al. Among authors: ghio r. Ann Hematol. 2006 Mar;85(3):174-80. doi: 10.1007/s00277-005-0044-6. Epub 2006 Jan 12. Ann Hematol. 2006. PMID: 16408206 Clinical Trial.
Quality of life and physicians' perception in myelodysplastic syndromes.
Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. Oliva EN, et al. Among authors: ghio r. Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25. Am J Blood Res. 2012. PMID: 22762033 Free PMC article.
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R. Balleari E, et al. Among authors: ghio r. Leuk Res. 2011 Nov;35(11):1472-6. doi: 10.1016/j.leukres.2011.05.025. Epub 2011 Jul 26. Leuk Res. 2011. PMID: 21794914
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
Olcese F, Clavio M, Rossi E, Spriano M, Ballerini F, Canepa L, Pierri I, Aquino S, Varaldo R, Manna A, Secondo V, Racchi O, Balleari E, Orcioni GF, Carella AM, Ghio R, Gobbi M. Olcese F, et al. Among authors: ghio r. Ann Hematol. 2009 Sep;88(9):855-61. doi: 10.1007/s00277-009-0699-5. Epub 2009 Feb 3. Ann Hematol. 2009. PMID: 19189105 Free article.
134 results